Carcinogen-DNA and Protein Adducts as Intermediate Biomarkers for Human Chemoprotection Trials
- 1 January 1994
- book chapter
- Published by Springer Nature
- Vol. 354, 149-160
- https://doi.org/10.1007/978-1-4899-0939-8_11
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Aflatoxin—albumin adducts in human sera from different regions of the worldCarcinogenesis: Integrative Cancer Research, 1990
- Biomarkers as Intermediate End Points in Chemoprevention TrialsJNCI Journal of the National Cancer Institute, 1990
- Protection by 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) against the hepatotoxicity of aflatoxin B1 in the ratToxicology and Applied Pharmacology, 1988
- Comparative effect of dietary butylated hydroxyanisole and β-naphthoflavone on aflatoxin B1 metabolism, DNA adduct formation, and carcinogenesis in rainbow troutCarcinogenesis: Integrative Cancer Research, 1988
- Aflatoxin B1 binding to plasma albumin and liver DNA upon chronic administration to ratsCarcinogenesis: Integrative Cancer Research, 1986
- Modification of aflatoxin B1 binding to DNA in vivo in rats fed phenolic antioxidants, ethoxyquin and a dithiothioneCarcinogenesis: Integrative Cancer Research, 1985
- The inhibitory effects of ethoxyquin on the carcinogenic action of aflatoxin B1 in ratsCancer Letters, 1983
- Detection of putative adduct with fluorescence characteristics identical to 2,3-dihydro-2-(7′-guanyl)-3-hydroxyaflatoxin B1 in human urine collected in Murang'a district, KenyaCarcinogenesis: Integrative Cancer Research, 1983